A weaker word than it sounds
"Preclinical" sounds like "almost clinical". It means "not in humans".
Preclinical studies are cell culture and animal models. They are how every drug begins, and they are genuinely informative: they establish mechanism, identify toxicity, and generate the hypothesis a trial then tests.
They are also where the overwhelming majority of promising compounds stop working.
"Over 100 preclinical studies": read carefully
You will often see "over 100 studies" quoted for BPC-157. We could not verify that number. In September 2026, PubMed listed about 230 records that mention BPC-157, reviews included. A 2025 systematic review of its muscle, tendon, ligament and bone research found 35 animal studies and 1 human study, with improved outcomes across those animal models. That is a real and unusual body of work, and consistency across that many models is meaningful.
It is also research in animals, not in people.
FDA's July 2026 review found five small human studies: an enema in 24 healthy people, a 53-person colitis trial, knee injections in 17 people, bladder injections in 12, and an IV drip in 2. None of them studied a tendon in an athlete, which is what almost everyone using BPC-157 is actually trying to do.
The honest position is that the mechanism is well characterised, the animal evidence is consistent, and the specific human application is unproven. All three of those are true at once, and the compound's popularity does not change any of them.
"Doubled running capacity in mice"
MOTS-C's headline finding. Mice treated with MOTS-C doubled their treadmill running capacity, and older treated mice outperformed untreated middle-aged mice.
Those are striking results and they are why the compound is interesting. They are also mice.
The human data is different in kind: exercise raises endogenous MOTS-C up to 12-fold in skeletal muscle, and people with diabetes and obesity have significantly lower circulating levels. That is observational. It establishes that MOTS-C is part of the exercise response, not that injecting it reproduces the effect.
A Phase 1 trial of a modified analog, CB4211, was reported by its developer as well tolerated. Safety, not efficacy. Those are separate questions and Phase 1 answers only the first.
Fragment versus parent
TB-500 is the sharpest case of a distinction that is easy to miss.
Thymosin Beta-4, the 43-amino-acid parent protein, has been studied extensively, including in human clinical trials for wound healing and dry eye, with a favourable safety profile.
TB-500 is a synthetic copy of amino acids 17 to 23. Seven residues. The fragment used in practice has not been studied separately in humans.
Vendors and articles routinely cite Thymosin Beta-4 research as TB-500 research. It is a related molecule that shares the parent's actin-binding stretch, and that is a reasonable basis for a hypothesis. It is not the same evidence: in the one cell-culture test of TB-500 itself, it did not close scratch wounds in cultured cells (FDA, May 2026).
Watch for this pattern generally: research on the parent compound, the natural form, or a modified analog being presented as research on the thing in the vial.
The questions worth asking of any claim
In what? Cell culture, mice, or people.
How many? Sixteen patients is not two thousand.
Of what exactly? The compound in the vial, or a relative of it.
Measuring what? Safety or efficacy. Surrogate marker or actual outcome.
Compared to what? Placebo-controlled, or before-and-after with no control.
Five questions. They will resolve most claims you encounter, and you can ask them without a biology degree.
The point is calibration, not cynicism
Our own stated differentiator: most peptide content online either hypes everything equally or is so cautious it is useless.
Preclinical data is not nothing. Dozens of consistent animal studies is a genuinely better position than one. It is simply a different category of knowledge from a randomised controlled trial, and pretending otherwise is how people end up disappointed by compounds that never promised what they were sold as promising.